Following the US drug agency’s decision, Nature examines the outlook for other hallucinogens that are in clinical trials as psychiatric treatments.

But Marks points out that the FDA typically follows the advice of its independent advisory committees — and the one that evaluated MDMA in June overwhelmingly voted against approving the drug, citing problems with clinical trial design that the advisers felt made it difficult to determine the drug’s safety and efficacy. One concern was about the difficulty of conducting a true placebo-controlled study with a hallucinogen: around 90% of the participants in Lykos’s trials guessed correctly whether they had received the drug or a placebo, and the expectation that MDMA should have an effect might have coloured their perception of whether it treated their symptoms.

Another concern was about Lykos’s strategy of administering the drug alongside psychotherapy. Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), the non-profit organization that created Lykos, has said that he thinks the drug’s effects are inseparable from guided therapy. MDMA is thought to help people with PTSD be more receptive and open to revisiting traumatic events with a therapist. But because the FDA doesn’t regulate psychotherapy, the agency and advisory panel struggled to evaluate this claim. “It was an attempt to fit a square peg into a round hole,” Marks says.

  • qaz@lemmy.world
    3·
    3 months ago

    It works super well, and most patients taking it in double blind trials find it relieves headache pain considerably. Why is it a bad thing, to the point of rejecting it as a treatment, that the patient feels that the pill is working very well and has concluded on their own that this is probably not a placebo?

    The problem is that it’s not a double blind trial because the participants can tell whether they are on it. The placebo effect is also a problem because there is no real control group.

    • rand_alpha19@moist.catsweat.com
      3·
      3 months ago

      But why is that such a problem that it’s worth rejecting what is otherwise widely considered an effective treatment?

      I am fundamentally not understanding the inherent risk to patients resulting from the structure of the study that is apparently so harmful that it must not continue.

      Why is being able to tell that your medication is working a negative thing in a study? And such a negative thing that it apparently negates all other positive aspects of the medication.

      • qaz@lemmy.world
        3·
        3 months ago

        The problem is that you can’t tell if it’s truly working due to the placebo effect.

        • rand_alpha19@moist.catsweat.com
          2·
          3 months ago

          Yeah, I understand that. But if there’s a measurable difference between the efficacy of the 2 pills that even the patient is obviously aware of, why does that warrant extreme caution versus another pill that doesn’t have this effect?

          Like why is it better to have a study in which the patient literally can’t tell the difference between treatments? Why is it not detrimental for a federal agency to unilaterally dismiss this?

          I understand that people online aren’t obligated to engage with me thoughtfully, but I was hoping for an actual explanation that is longer than 50 words from someone who is more knowledgeable than me regarding the validity of scientific experiments as they relate to pharmaceuticals.

          • Hamartiogonic
            2·
            3 months ago

            The idea of modern medicine is to sell chemical compounds that actually have an effect. It’s a philosophical and ethical thing. All products have a unique psychological effect that gets intertwined with their biochemical effect. If you can’t study them individually, it’s impossible to tell if the biochemical effect even exists at all. If your medicine relies heavily, or even entirely, on the psychological side, it’s no different than homeopathy. The idea of modern medicine is to be better than the old stuff that preceded it.

            I prefer to think of this as an equation like this: Pm+Bm=Pp+Bp

            Pm=psychological effect, medicine

            Bm=biochemical effect, medicine

            Pp=psychological effect, placebo = surprisingly big

            Bp=biochemical effect, placebo = 0

            If these sides are equivalent, the medicine is just as effective as placebo. If the medicine side is bigger, you’ll want to know how much of it comes from the P and B terms. In order to figure that out, you would need to know some values. Normally, you can just assume that Pm=Pp, but if you can’t assume that, it you’re left with two unknowns in that equation. In this case, you really can’t assume them to be equal, which means that your data won’t allow you to figure out how much of the total effect comes from psychological and biochemical effects. It could be 50/50, 10/90, who knows. That sort of uncertainty is a serious problem, because of the philosophical and ethical side of developing medicine.

            • qaz@lemmy.world
              3·
              3 months ago

              biochemical effect, placebo = 0

              I’m not sure if the biochemical effects of a placebo are 0.

              In conditioning, a neutral stimulus saccharin is paired in a drink with an agent that produces an unconditioned response. For example, that agent might be cyclophosphamide, which causes immunosuppression. After learning this pairing, the taste of saccharin by itself is able to cause immunosuppression, as a new conditioned response via neural top-down control. Such conditioning has been found to affect a diverse variety of not just basic physiological processes in the immune system but ones such as serum iron levels, oxidative DNA damage levels, and insulin secretion. Recent reviews have argued that the placebo effect is due to top-down control by the brain for immunity and pain. Pacheco-López and colleagues have raised the possibility of “neocortical-sympathetic-immune axis providing neuroanatomical substrates that might explain the link between placebo/conditioned and placebo/expectation responses”. There has also been research aiming to understand underlying neurobiological mechanisms of action in pain relief, immunosuppression, Parkinson’s disease and depression.

              Shamelessly stolen from Wikipedia because I couldn’t find the original source